After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma? [Microdose]
Friday, October 10, 2025 1 min read
Key Takeaway: AbbVie has made a significant investment of $1.2 billion in Gilgamesh Pharmaceuticals for Bretisilocin, indicating a shift in the perception of psychedelic therapies. These treatments are now considered a promising avenue in psychiatry, focusing on rebuilding neural architecture rather than merely adjusting serotonin levels. This marks a notable evolution in mental health treatment strategies.
Price reaction · baseline $8.4564 (2025-10-09 close) · hit pre-market · 6 other ENVB headline(s) in the window, move may be shared
day 0 close
-11.3%
day 1
-8.4%
day 3 · peak
+27.7%
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie's investment highlights growing interest in psychedelic therapies.
Psychedelic-inspired therapeutics are seen as a promising frontier in psychiatry.
The approach focuses on rebuilding neural architecture, offering innovative treatment potential.
Full Press Release Details
When AbbVie wrote a $1.2 billion cheque for Gilgamesh Pharmaceuticals’ Bretisilocin, it wasn’t just buying a drug, it was buying a future. That future, once dismissed as fringe science, is now being reframed as one of the most promising frontiers in modern psychiatry: psychedelic-inspired therapeutics that heal the brain not through serotonin tweaks, but by rebuilding neural architecture itself.
Full Article >>
Frequently Asked Questions
What did AbbVie invest in?
AbbVie invested $1.2 billion in Gilgamesh Pharmaceuticals for Bretisilocin.
Why are psychedelic therapies important?
They are considered a promising frontier in modern psychiatry for mental health treatment.
How do psychedelic therapies work?
They aim to rebuild neural architecture rather than just adjusting serotonin levels.
What does this investment signify?
It indicates a growing interest in psychedelic-inspired therapeutics in the pharmaceutical industry.